SCHEMBL6822005

SCHEMBL6822005

COc1ccn2nc(-c3ccccc3)c(C(C)=O)c2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.45
CSF1R P07333 1/20 0.43
FGFR1 P11362 1/20 0.43
FLT1 P17948 1/20 0.43
KDR P35968 1/20 0.43
CSNK1A1 P48729 1/20 0.43
CDK8 P49336 1/20 0.43
GSK3A P49840 1/20 0.43
GSK3B P49841 1/20 0.43
CDK5 Q00535 1/20 0.43
PRKCQ Q04759 1/20 0.43
LRRK2 Q5S007 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
DYRK1B Q9Y463 1/20 0.43
PTGER1 P34995 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
NR1H2 P55055 1/20 0.42
NR1H3 Q13133 1/20 0.42
LMNA P02545 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6822096 0.84 EGFR (0.56) EGFRMAPTHTTLMNAKDM4E
SCHEMBL6822071 0.81 EGFR (0.46) EGFRCSF1RFGFR1FLT1KDR
SCHEMBL1936155 0.80 DHODH (0.41) PTGER1LMNAKDM4EHSD17B10MEN1
SCHEMBL5216599 0.80 GABRP (0.43) MAPTLMNAMEN1KMT2A
SCHEMBL7665680 0.79 EGFR (0.61) EGFRCSF1RFGFR1FLT1KDR
SCHEMBL13459288 0.77 SRC (0.44) LMNARIPK2
SCHEMBL1936125 0.77 LMNA (0.45) EGFRMAPTLMNAKDM4EHSD17B10
SCHEMBL1934938 0.75 MAPK14 (0.39) CDK5MAPTLMNAKDM4EEPHB3
SCHEMBL18357700 0.74 KDM4E (0.43) MAPTLMNAKDM4EHSD17B10EPHB3
SCHEMBL28992989 0.73 IDO1 (0.43) LMNAKDM4EHSD17B10BAZ2BBAZ2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof ADRB1, ADRA1D, ADRB3 EGFR 3229/4885CSF1R 2171/4885FGFR1 1855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.